73.42USD-1.45%Mkt Cap: —P/E: —1d ago
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value1.87B $
Revenue (TTM)54.59M $
Gross Profit54.59M $
Net Income (TTM)-157.13M $
Revenue/Share2.247 USD
Last Price73.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees63
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS6402681083
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-14.40
EV/Revenue34.29
P/S—
P/B2.80
EPS (TTM)—
EPS (Forward)—
52W Range
70.0052% of range76.53
52W High76.53 USD
52W Low70.00 USD
Profitability
Gross Margin100.00%
Oper. Margin-412.23%
EBITDA Margin-238.05%
Profit Margin-287.84%
ROE-35.76%
ROA-12.54%
Growth
Revenue Growth-9.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-233.79M $
CapEx (TTM)—
FCF Margin-246.87%
FCF Yield—
Net Debt-548.41M $
Net Debt/EBITDA4.22
Balance Sheet
Debt/Equity15.05
Current Ratio10.42
Quick Ratio9.71
Book Value/Sh26.46 USD
Cash/Share20.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float28.53M
Insiders0.44%
Institutions106.16%
Technical
SMA 50—
SMA 200—
Beta1.16
S&P 52W Chg20.80%
Avg Vol (30d)551
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—